Scarica l'app Stockscreener
6.79
3.11%
0.205
Pre-mercato:
6.58
-0.21
-3.09%
Precedente Chiudi:
$6.585
Aprire:
$6.63
Volume 24 ore:
2.40M
Relative Volume:
1.16
Capitalizzazione di mercato:
$498.51M
Reddito:
$161.10M
Utile/perdita netta:
$-308.60M
Rapporto P/E:
-1.454
EPS:
-4.67
Flusso di cassa netto:
$-259.90M
1 W Prestazione:
-10.78%
1M Prestazione:
-12.84%
6M Prestazione:
-62.17%
1 anno Prestazione:
-72.35%
Intervallo 1D:
$6.44
$6.895
Intervallo di 1 settimana:
$6.055
$7.13
Portata 52W:
$5.90
$29.61
Arvinas Inc Stock (ARVN) Company Profile
Nome
Arvinas Inc
Settore
Industria
Telefono
203-535-1456
Indirizzo
395 WINCHESTER AVE, NEW HAVEN, CT
Confronta ARVN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
6.79 | 483.45M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-02 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-05-05 | Downgrade | Truist | Buy → Hold |
| 2025-05-02 | Downgrade | Jefferies | Buy → Hold |
| 2025-05-02 | Downgrade | TD Cowen | Buy → Hold |
| 2025-03-13 | Downgrade | Goldman | Buy → Neutral |
| 2025-03-12 | Downgrade | Wedbush | Outperform → Neutral |
| 2025-03-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-10 | Iniziato | BTIG Research | Buy |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-02-28 | Reiterato | Oppenheimer | Outperform |
| 2024-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-01 | Iniziato | Goldman | Buy |
| 2023-12-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-11-20 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-10-23 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-01-12 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-01-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | Iniziato | Barclays | Overweight |
| 2022-06-21 | Iniziato | Jefferies | Hold |
| 2022-05-09 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-04-06 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-02-11 | Ripresa | BMO Capital Markets | Outperform |
| 2022-02-10 | Iniziato | Wells Fargo | Overweight |
| 2022-01-19 | Iniziato | Goldman | Buy |
| 2021-12-07 | Iniziato | Cowen | Outperform |
| 2021-10-14 | Iniziato | SVB Leerink | Outperform |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-09-09 | Iniziato | BofA Securities | Buy |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-21 | Iniziato | Truist | Buy |
| 2021-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-12-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-06-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-05-12 | Iniziato | Oppenheimer | Perform |
| 2019-12-19 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-25 | Iniziato | Guggenheim | Buy |
| 2019-10-24 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-09-25 | Iniziato | Wedbush | Outperform |
| 2019-09-12 | Iniziato | BMO Capital Markets | Outperform |
| 2019-08-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-06-05 | Downgrade | Citigroup | Buy → Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-10-22 | Iniziato | Citigroup | Buy |
| 2018-10-22 | Iniziato | Goldman | Neutral |
| 2018-10-22 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Arvinas Inc Borsa (ARVN) Ultime notizie
Arvinas (NASDAQ:ARVN) Given New $15.00 Price Target at Guggenheim - MarketBeat
Arvinas FY2025 EPS Estimate Lowered by Cantor Fitzgerald - MarketBeat
HC Wainwright Has Lowered Expectations for Arvinas (NASDAQ:ARVN) Stock Price - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Metastatic Prostate Cancer Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Merck Sharp & Dohme, Arvinas Androgen Receptor, UNICANCER, Aragon Pharma, Mark Stein, Novartis, Orion - Barchart.com
Pfizer and Arvinas' breast cancer therapy to be reviewed by FDA - MSN
FDA gives Arvinas and Pfizer’s vepdegestrant NDA for breast cancer - Yahoo Finance
Arvinas (NASDAQ:ARVN) Price Target Cut to $16.00 by Analysts at Wells Fargo & Company - MarketBeat
Q3 Earnings Forecast for Arvinas Issued By Leerink Partnrs - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Shares Acquired by XTX Topco Ltd - MarketBeat
Arvinas and Pfizer’s FDA Nod for Cancer Drug - The Globe and Mail
Arvinas, Inc. (NASDAQ:ARVN) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - 富途牛牛
Arvinas (NASDAQ:ARVN) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
FDA Accepts Arvinas, Pfizer's Vepdegestrant NDA for Breast Cancer Treatment - AInvest
FDA to Review Pfizer and Arvinas' Breast Cancer Therapy Vepdegestrant by June 5, 2026. - AInvest
Arvinas' Breakthrough in PROTACs: A Catalyst for Valuation Re-Rating in Oncology's New Frontier - AInvest
Arvinas Q2 2025 Earnings: Revenue Down, Clinical Progress & New CEO Announcement - AInvest
Arvinas, Pfizer announce FDA acceptance of vepdegestrant NDA - TipRanks
Arvinas and Pfizer Announce FDA Acceptance of NDA for Vepdegestrant Following Positive Phase 3 VERITAC-2 Trial Results in Advanced Breast Cancer - Quiver Quantitative
Arvinas Announces FDA Acceptance of the New Drug - GlobeNewswire
ARVNArvinas Latest Stock News & Market Updates - Stock Titan
Arvinas Holding Company (ARVN) Gets a Buy from Guggenheim - The Globe and Mail
Arvinas Holding’s Strategic Uncertainties and Partnership Challenges Justify Hold Rating - TipRanks
A Quick Look at Today's Ratings for Arvinas(ARVN.US), With a Forecast Between $9 to $18 - 富途牛牛
Arvinas (ARVN) Shares Plunge 2.95% to 2025 Low Amid Mixed Clinical Results and Partnership Uncertainty - AInvest
Arvinas 2025 Q2 Earnings Record Net Income Despite Worsening Losses - AInvest
Arvinas, Pfizer reworking partnership on ‘Protac’ cancer drug - BioPharma Dive
Arvinas signals CEO transition and extends cash runway into H2 2028 amid vepdeg collaboration changes - MSN
Wall Street Has Mixed Opinions On Future Of Arvinas’ Investigational Drug: Retail’s Got A Cautious Approach - Stocktwits
Wedbush Cuts Price Target on Arvinas to $10 From $12, Keeps Neutral Rating - MarketScreener
Arvinas price target raised to $24 from $18 at H.C. Wainwright - TipRanks
Arvinas, Inc. (NASDAQ:ARVN) Q2 2025 Earnings Call Transcript - Insider Monkey
Arvinas (NASDAQ:ARVN) Is In A Good Position To Deliver On Growth Plans - 富途牛牛
Guggenheim lowers Arvinas stock price target to $15 on partnership concerns - Investing.com
Insider Sellers Might Regret Selling Arvinas Shares at a Lower Price Than Current Market Value - simplywall.st
Arvinas Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Arvinas Holding Company: Strong Cash Position and Promising Pipeline Justify Buy Rating - TipRanks
Federated Hermes Inc. Purchases 933,183 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas Reports Q2 2025 Financials and Drug Developments - TipRanks
Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Arvinas Earnings Call: Balancing Progress and Challenges - TipRanks
Arvinas Q2 2025 Earnings Call Transcript - MarketBeat
ARVINAS, INC. SEC 10-Q Report - TradingView
Arvinas Holding Company: Hold Rating Amid Modest Data and Strategic Uncertainties - TipRanks
Arvinas shares fall 16.16% intraday after Q2 revenue drops 71% and net loss widens. - AInvest
Earnings call transcript: Arvinas Q2 2025 results show revenue miss, stock drops - Investing.com Canada
Arvinas, Inc. (ARVN) Reports Q2 Loss, Misses Revenue Estimates - sharewise.com
Arvinas earnings beat by $0.10, revenue fell short of estimates - Investing.com Canada
Arvinas Inc (ARVN) Q2 2025 Earnings: EPS Beats Estimates at -$0. - GuruFocus
Arvinas reports Q2 EPS (84c), consensus (89c) - TipRanks
Arvinas Q2 revenue falls 71%, net loss widens - MarketScreener
Arvinas Inc Azioni (ARVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):